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surement as the primary post-operative biochemical tumor-marker for differentiated thyroid cancers
(DTC). During this period, the role of serum Tg autoantibody (TgAb) testing has evolved from being
merely a test for thyroid autoimmunity, to being one ordered simultaneously with Tg to conﬁrm the
absence of TgAb interference. In recent years this qualitative TgAb role (positive or negative result)
became expanded with the recognition that TgAb concentrations (measured in kIU/L) respond to
changes in the mass of Tg-secreting thyroid tissue [1]. As a result, serum TgAb has evolved as a sur-
rogate DTC tumor-marker test that can replace Tg immunometric assay (IMA) measurements that are
compromised by TgAb interference [1–10]. Unfortunately, a number of methodologic factors negatively
impact the clinical value of TgAb testing. These include insensitivity, the inappropriately high cut-off
values that manufacturers set for diagnosing thyroid autoimmunity rather than detecting TgAb
interference with Tg measurements, and interference from high endogenous Tg concentrations [1–
5,7,10–17]. Current TgAb methods are primarily non-isotopic, automated and use either competitive
or non-competitive IMA formats. Most methods are standardized against the International Reference
Preparation (IRP MRC 65/93) and report TgAb values in kIU/L, yet between-method numeric serum
TgAb values vary by factors of more than 100-fold that are patient-speciﬁc [16]. The cause for this
variability is likely two-fold – differences in the methodologic speciﬁcity for recognizing the different
Tg epitopes in endogenous Tg versus the Tg reagent(s), compounded by patient-speciﬁc serum TgAb
heterogeneity. The practical consequences of these speciﬁcity differences is that serial TgAbmonitoring
of DTC patients can only be made by using the same method.
2. Strengths and pitfalls of current TgAb immunoassay methods
Serum TgAb measurement began ﬁve decades ago with insensitive qualitative techniques
employing immunodiffusion, complement ﬁxation, passive particle agglutination and indirect
immunoﬂuorescence tests. These early methods were phased out in the 1970s in favor of semi-
quantitative passive hemagglutination tests reported in titers that are still used by a minority of lab-
oratories [11]. Subsequently, more sensitive competitive radioassays that detected TgAb as a function of
125I-Tg binding and reported results in kIU/L relative to the International Reference Preparation (IRP)
MRC 65/93 became available, and are still used by some laboratories [4,8,10,16,18]. In the last ten years,
most laboratories have adopted non-isotopic, non-competitive, automated TgAb methods in prefer-
ence to isotopic radioassays or hemagglutination tests [8,12–17].
Most current TgAb methods claim to be standardized against the IRP MRC 65/93 and report results
in kIU/L [8,16,17]. However, despite IRP standardization, analytical sensitivity limits and the cut-off
values that manufacturers recommend to deﬁne a “positive” TgAb result vary 200-fold [8,12,14–18].
It should be noted that this IRP is a 60-year old preparationmade from blood products containing TgAb
with Tg epitope speciﬁcities originally characteristic of thyroid autoimmunity that may have been
changed by aging. Also of note is that eachmethod is not directly standardized with the IRP but instead
uses its own internal, proprietary TgAb standard. Tg epitope speciﬁcity differences between the IRP and
these secondary standards likely contribute to the widely discrepant numeric TgAb values reported
when the same serum specimen is measured by different methods. For example, one study of doubling
dilutions of the IRP reported similar potency (in kIU/L) between two different methods yet a ten-fold
difference between serum values [17]. Clearly the Tg epitope speciﬁcities of TgAb in sera differ when
measuring the IRP versus the secondary assay standards. In general, serum TgAb concentrations appear
to correlatewith both the number of Tg epitopes recognized and the degree of restriction of the epitope
speciﬁcities [19]. TgAb–Tg epitope heterogeneity in DTC sera is evident from studies showing that
despite a broad ranking of values between different methods, individual sera display widely variable
relationships across methods [4,10–12,14–17]. Glycosylation studies and epitope mapping using
monoclonal antibodies or fragment antigen-binding (Fab) probes, suggest that TgAb associated with
papillary thyroid cancers (PTC) may arise from two distinctly different pathologic mechanisms – either
underlying autoimmune thyroid disease (histologic lymphocytic thyroiditis) or an immune response to
the inﬂammation associated with tumorogenesis that may promote the release of post-translational
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geneous speciﬁcity of TgAb in patient sera and why TgAb detected by one method may not be detected
by another [14–17]. It appears that each patient’s TgAb has a characteristic IgG subclass and speciﬁcity
for recognizing the Tg assay reagent(s) [25,24]. As a result, the same serum produces different TgAb
numeric results with differentmethods [8,12,14–18]. The characteristics of any patient’s TgAb appear to
be ﬁxed such that the ratios between the numeric values reported when comparing two different
methods appear to be a patient-related constant, and independent of changes in TgAb concentration
(measured by the same method), as shown in Fig. 1 [10]. This ﬁxed ratio can be used to establish new
baseline values for a patient without disrupting serial TgAb monitoring, should a change in TgAb
method become necessary. This is provided that a specimen(s) is available for establishing the ratio
between the new versus old TgAb method values, either because the laboratory gives physicians
advanced notice of a method change (which generally does not occur), or there are archived frozen
specimens available for measurement by the new method. Obviously, the stability of TgAb in frozen
archived sera critically impacts the value of this re-baselining strategy. Short-term stability studies of
serum Tg (IMA) and TgAbmeasurements have suggested that specimen stability relates to storage time
and temperature, the number of freeze/thaw cycles, and whether there is sufﬁcient specimen volume
to minimize evaporation [26–29]. Two recent studies using the same Tg method (Roche) reported no
loss of Tg or TgAb immunoactivity when specimens were refrigerated for up to 24 h, or stored for 2–3
weeks at 20 C, but a progressive loss of immunoactivity during longer-term frozen storage [29]. The
practice of storing all specimen left after Tg þ TgAb testing in a frozen (20 C) archive allows phy-
sicians to request concurrent re-measurement of a past specimen alongside the patient’s current
specimen as a way to eliminate between-run variability and conﬁrm a suspicious rising Tg and/or TgAb
trend (see section 6 ‘TgAb trends during long-term follow-up monitoring’). Fig. 2 shows stability data
using the same in-house Tg RIA, TgAb (Kronus/RSR) and Tg IMA (Beckman Access) methods [8,30] for
concurrent re-measurement of frozen (20 C) archived sera stored for either between 1 and 4 years orFig. 1. Mean  sd of the ratios between the numeric values (kIU/L) reported by a test method, Roche (solid circles); Beckman (open
triangles); Nichols Advantage (open circles) or Siemens Immulite (closed squares), divided by the numeric values of the reference
method (Kronus/RSR) for individual DTC patients with 3 or more serial serum specimens sent for TgAb testing as a component of
serial serum Tg monitoring over a period of 1–4 years.
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specimen volume was stored to minimize evaporation and that sera were subjected to no more than
two freeze/thaw cycles (Fig. 2).3. Tg recovery tests are unreliable for detecting interfering TgAb
For the last three decades, the presence of interfering TgAb has been determined either directly by
TgAb immunoassay (Section 2) or indirectly by employing a Tg recovery test. Recovery tests typically
involve measuring the Tg concentration before and after a known amount of Tg has been added to an
aliquot of the test serum. Recoveries greater than 80% are typically considered to indicate the absence
of interferences, thereby validating the Tg measurement [6,7,26,31–35]. In order for the recovery of an
exogenous Tg preparation to mimic interactions between the endogenous Tg and TgAb components,
the added and endogenous Tg should be immunologically identical, the amount of Tg added should
not exceed the concentration of the endogenous Tg and there should be sufﬁcient time allowed for
the added Tg to equilibrate with the endogenous Tg and TgAb serum constituents before initiating the
Tg IMA test. These criteria are not usually met. First, there can be three different types of Tg antigen
present in the recovery test tube that can differ in structure and thereby the epitopes available for
TgAb binding, these would be (1): the exogenous (added) Tg which is usually a thyroid gland extract
(2), normal Tg secreted by normal remnant tissue, and (3) abnormal tumor-derived Tg isoforms.
Second, because Tg IMA tests preferentially measure free Tg, any exogenous Tg added in excess of the
endogenous (serum) Tg would tend to saturate TgAb binding sites and cause an excess of free
exogenous Tg that would falsely elevate the recovery. Some manufacturers have recognized this
potential problem and have reduced the mass of exogenous Tg [36]. However, it appears that reducing
the amount of Tg added is less important than allowing time for constituents to equilibrate before
initiating the IMA test. In one study that used a low concentration of exogenous Tg (w10 mg/L) and an
18 h incubation to allow the added Tg to equilibrate with the endogenous Tg and TgAb constituents,
the recovery of exogenous Tg was reduced by as much as 20% compared with initiating the IMA
reaction without allowing time for equilibration [32]. This problem of disequilibrium may wellFig. 2. The stability of (a) TgAb (Kronus/RSR), (b) an in-house Tg RIA and (c) Tg IMA (Beckman Access) concurrent re-measurements
made in frozen (20 C) archived sera stored for either between 1 and 4 years (open circles) or over ﬁve years (closed circles) [8,30].
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[4,6–8,15,32,35]. In addition to the many technical limitations of using a recovery approach for
detecting interfering TgAb, a further disadvantage is that recoveries cannot be used to “correct” the Tg
result for TgAb interference, or quantitatively measure TgAb as a surrogate tumor marker test (see
Section 6).
4. TgAb interference with Tg measurement
As shown in Table 1, there are three classes of Tg method having different propensities for TgAb
interference: Radioimmunoassays (RIA), Immunometric assays (IMA) and Liquid Chromatography-
Tandem Mass Spectrometry (LC-MS/MS) tests.
 Tg Radioimmunoassays (RIA): Tg RIAs were ﬁrst developed in the 1970s and quantify Tg as a
function of the competition between endogenous Tg and a 125I-Tg reagent for a limited amount of
polyclonal (rabbit) Tg antibody [37]. Because RIAs suffer from the dual disadvantages of being
isotopic and requiring long incubation times (days) to maximize functional sensitivity (FS) [38]
they have been mostly replaced by IMA methods that require shorter incubations (hours), are
mostly non-isotopic, and can be automated [8].
 Tg Immunometric assays (IMA): Despite the greater FS potential of IMA versus RIA methodology,
the ﬁrst generation of IMA tests only achieved comparable FS to RIA (0.5–1.0 mg/L) [8,30,38]. More
recently, a second generation of Tg IMAs, characterized by an order of magnitude better FS (0.05–
0.10 mg/L) are rapidly becoming the standard of care in thewake of studies showing that the clinical
utility of Tg testing is enhanced by assay sensitivity, and that second generation FS obviates the
need for expensive recombinant human Thyroid Stimulating Hormone (TSH) TSH-stimulated Tg
testing [30,39,40].
 Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Tests: In response to the bur-
geoning ﬁeld of proteomics a new class of Tg method, i.e., liquid chromatography-tandem massTable 1
Classes of Tg method.
Assay class Principle Turn-around
time
(ease of
automation)
 Functional sensitivity (FS) [38]
 Strengths/pitfalls
Radioimmunoassay
(RIA)
1973 – present
Competitive – uses a
limited quantity of
polyclonal antibody (PAb)
w6 days
(difﬁcult to
automate)
 FS w 0.50 mg/L [8,16]
 PAbs – broad epitope
speciﬁcity for detecting
abnormal tumor Tg isoforms
 no HAMAa interference
 resistant to TgAb interference
Immunometric
Assay (IMA)
1990 – present
Non-competitive – uses
capture and signal
monoclonal antibodies
(MAbs)
Hours
(easy to
automate)
 FS range ¼ 0.05–1.0 mg/L [8,30]
 prone to HAMAa & TgAb
interferences
 MAbs – limited Tg epitope
speciﬁcities for detecting
abnormal tumor Tg isoforms
Liquid Chromatography–
Tandem Mass
Spectrometry
(LC-MS/MS)
2009 – present
Specimens may be
concentrated and/or reduced,
alkylated and digested
with Trypsin before target
peptides are immunoafﬁnity
enriched prior to detection
by LC-MS/MS [44,48,49]
1–2 days
(specimen
preparation
difﬁcult to
automate)
 FS 1.0–2.0 mg/L [49]
 may avoid interference from
TgAb or HAMAa [49]
 polymorphic tumor Tg may
fail to yield target peptides
 no clinical studies as yet
a HAMA ¼ human anti-mouse antibody.
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to overcome TgAb (and other interferences) by using Trypsin to digest Tg bound to TgAb and
release a target Tg peptide that can be immunoafﬁnity enriched before being detected by LC-MS/
MS. These methods involve extensive specimen preparation before the trypsin treatment(s). They
currently only achieve ﬁrst generation functional sensitivity [44,48,49].
The RIA class of Tg method appears more resistant to TgAb interference than the IMA class of
method, although falsely low or high Tg RIA values can occur, depending on the interactions between
the endogenous Tg and TgAb in the serum and the speciﬁcity of the RIA ﬁrst and second antibody
reagents [8,16,41–44]. The major disadvantage of the IMA class of method is their propensity for
interference from even very low concentrations of TgAb [4,6–8,45]. This interference is characterized
by falsely low/undetectable serum Tg values and is thought to result when free Tg is complexed by
endogenous TgAb and is sterically hindered from binding to the capture and/or signal monoclonal
antibody reagents and/or alternatively, endogenous TgAb binding to Tg masks the epitopes needed for
recognition by the monoclonal antibody reagents. Evidence that TgAb interference causes under-
estimated Tg IMA values is seen by in vitro serum mixing studies [7,26,45] and supported by clinical
data showing paradoxically undetectable serum Tg IMA values for some TgAb-positive euthyroid
subjects with functioning thyroid glands [8], TgAb-positive untreated Graves’ hyperthyroid patients
[34,46] and TgAb-positive DTC patients with persistent/recurrent disease [4–6,9,47]. Early Tg LC-MS/
MS studies of TgAb-positive sera report higher Tg LC-MS/MS and Tg RIA values as compared with Tg
IMA, suggesting that Tg is indeed present in many sera with detectable Tg RIA yet undetectable Tg IMA
values [16,44]. Whereas these early data afﬁrm that TgAb interference causes Tg IMA underestimation,
even were reliable Tg measurements available the signiﬁcance of serum Tg changes in the presence of
TgAb may be different if there is accelerated clearance of Tg complexed with TgAb [50,51]. The pre-
liminary LC-MS/MS data also supports the use of Tg IMA/Tg RIA discordance as an independent in-
dicator for TgAb interference [4,6,16,52,53]. Studies using a low Tg IMA/Tg RIA ratio to indicate the
presence of TgAb interference ﬁnd that the propensity for TgAb interference with IMA is related to the
TgAb concentration, although high TgAb levels do not necessarily produce interference and TgAb
below the level of detection by some methods may profoundly interfere [4,10,16,32,45,53]. In some
cases discordance is seen in the absence of a detectable TgAb as a result of TgAb method insensitivity
(discussed in Section 2) or because the TgAb lacks the speciﬁcity to interact with the Tg assay re-
agent(s). Likewise, the absence of Tg IMA/Tg RIA discordances at high TgAb concentrations could reﬂect
either limited TgAb speciﬁcity, or result from a high endogenous Tg saturating TgAb binding sites and
leaving more free Tg for the IMA to detect. Consequently, the frequency of Tg IMA/Tg RIA discordance
(Fig. 3a) and the propensity for reporting falsely undetectable Tg IMA results (Fig. 3b) would be
reduced at high Tg concentrations, especially when TgAb is low. Conversely, when the endogenous Tg
is low, the Tg would primarily be bound to TgAb and would be rendered inaccessible for binding to the
IMA monoclonal antibodies. Under these circumstances the frequencies of both Tg IMA/Tg RIA
discordance (Fig. 3a) and falsely undetectable Tg IMA values (Fig. 3b) would be high, especially when
TgAb is high.5. Clinical signiﬁcance of TgAb detected during management of DTC
TgAb prevalence
Over the last two decades, the prevalence of TgAb reported for patients diagnosed with DTC has
varied between 8 and 36% and is approximately two-fold higher in DTC compared with the general
population (24.9 versus 10.1%, respectively) [2–5,7,54,57]. The differences in TgAb prevalence in DTC
reﬂect differences in methodologic sensitivities, speciﬁcities and the cut-offs used for a “positive” TgAb
(see Section 2), as well as factors relating to the ascertainment biases of the different study cohorts.
Speciﬁcally, TgAb prevalence increases with age and/or the proportion of females in the cohort and is
higher in papillary versus follicular thyroid cancers [3]. TgAb prevalence rises with iodine supple-
mentation of iodine deﬁcient populations along with an increase in prevalence of thyroid
Fig. 3. How the relationship between serum Tg and TgAb concentrations relate to the propensity for TgAb interference, as judged by
a low (<75%) Tg IMA/Tg RIA ratio (panel a) and an undetectable Tg IMA (<0.10 mg/L) associated with an unequivocally detectable Tg
RIA (1.0 mg/L) [21]. The Tg RIA and Tg IMA data is shown for nine groups of DTC patients with Tg RIA values in the low (1–5 mg/L),
intermediate (5–20 mg/L), or high (>20 mg/L) range, and TgAb concentrations in the low (1–5 kIU/L), intermediate (5–100 kIU/L) or
high (>100 kIU/L) range. The data, was taken from reference [10].
C. Spencer, S. Fatemi / Best Practice & Research Clinical Endocrinology & Metabolism 27 (2013) 701–712 707autoimmunity (Hashimoto’s thyroiditis) and an increased prevalence of papillary relative to follicular
thyroid cancers [55,56]. Given the strong association between the presence of TgAb and lymphocytic
thyroiditis, an association between Hashimoto’s thyroiditis and thyroid cancer (primarily PTC) has
been proposed and recently conﬁrmed by meta-analysis [13,58–61]. This association appears to be
supported by surgical studies made over the last 25 years that ﬁnd on average 27.6% of patients
receiving a thyroidectomy for PTC have histologic evidence of Hashimoto’s thyroiditis (relative risk
1.59, 1.15–4.16) [60]. However, contrary to this, Hashimoto’s thyroiditis is not generally considered a
risk factor for DTC. Indeed, ﬁne-needle aspiration biopsy studies ﬁnd no association between cytologic
lymphocytic thyroiditis and PTC (relative risk 0.69, 0.39–1.00), suggesting that Hashimoto’s thyroiditis
does not predispose to DTC [60]. It thus appears that any association between lymphocytic thyroiditis
and PTC may not relate to Hashmoto’s thyroiditis per se, but be secondary to chronic TSH stimulation,
biomolecular commonalities linking the two conditions, or a process relating to chronic inﬂammation
[10,23,59,60,62].
Prognostic signiﬁcance of detecting TgAb at time of diagnosis
When evaluating patients with a thyroid nodule, the presence of circulating TgAb may be a risk
factor for malignancy independent of thyroid autoimmunity or a detectable serum Thyroid peroxidase
antibody [58,63]. Furthermore, studies ﬁnd that patients with TgAb detected shortly after thyroidec-
tomy have a higher risk for persistent/recurrent disease during long-term follow-up [5,64–66], and the
higher the TgAb, the higher the risk [9]. However, thyroid antibodies are strongly associated with the
histologic presence of lymphocytic thyroiditis [5,7,13,47,67,68]. The higher frequency of recurrences in
TgAb-positive patients appears at odds with studies suggesting a more favorable outcome when PTC is
associated with lymphocytic thyroiditis [58,59,67–73]. However, such outcome studies have not al-
ways achieved signiﬁcance using multivariate analysis or distinguished between the generalized
lymphocytic inﬁltration characteristic of Hashimoto’s thyroiditis and non-speciﬁc tumor-inﬁltrating
lymphocytes that could represent an immune response to tumor that could favorably inﬂuence
prognosis [67,68,71,74]. Also, because PTC typically afﬂicts younger female patients with smaller and
lower grade tumors, factors other than the lymphocytic thyroiditis per se might favorably inﬂuence
outcome [10,70,72,75]. Offsetting this are reports that PTC associated with lymphocytic thyroiditis may
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node metastases and an increased risk of recurrences [3,5,10,63,66,68,72]. Clearly long-term pro-
spective studies are needed to elucidate whether the association between PTC and lymphocytic
thyroiditis is cause or effect, and whether lymphocytic thyroiditis per se has an independent inﬂuence
on outcome. The association between lymphocytic thyroiditis and the presence of TgAb has some
practical implications for patientmanagement.When thyroid tissue is still present shortly after surgery
for PTC, serum Tg tends to be lower (even undetectable) when histologic lymphocytic thyroiditis is
seen, as compared with PTC without lymphocytic thyroiditis [7,76,77]. Given the strong association
between lymphocytic thyroiditis and the presence of TgAb, this likely reﬂects TgAb interference with
serum Tg measurements, even when TgAb is reported as “negative” given the TgAb assay detection
problems discussed in Section 2. This suggests that it is important to review the pathology report for
histologic evidence of lymphocytic thyroiditis, because when present, there is a higher risk of occult
TgAb producing falsely low or undetectable Tg IMA values that have the potential to negatively impact
post-operative management decisions.
6. Clinical utility of monitoring TgAb trends as a surrogate tumor marker test
With the recognition that TgAb concentrations respond to changes in the mass of Tg-secreting
thyroid tissue [1], it is clear that monitoring changes in the TgAb concentration has more clinical
value as surrogate DTC tumor-marker than measuring TgAb merely as a qualitative (positive versus
negative) test for validating that a Tg measurement is free from TgAb interference [59]. When used
qualitatively, TgAb test parameters such as sensitivity, speciﬁcity and the cut-off value used to deﬁne a
“positive” TgAb result are of paramount importance. When used quantitatively as a surrogate tumor-
marker, an added requirement is that the between-run precision (% coefﬁcient of variation) of the TgAb
test is below 10% across 12–18 month follow-up intervals typical for monitoring DTC patients after the
ﬁrst post-operative year.TgAb changes during the early post-operative period (ﬁrst post-operative year)
A transient, (wtwo-fold) rise, or de novo appearance of, TgAb is seen in approximately 40% of pa-
tients studied 4–8 weeks after thyroidectomy, before any radioiodine treatment [7]. This rise appears
unrelated to the preoperative Tg or TgAb concentration or recurrence risk, and is likely the immune
response to the acute release of a large amount of Tg antigen by the trauma of surgery. Thereafter, the
magnitude of TgAb change has been shown to have prognostic signiﬁcance [47]. Patients whose TgAb
concentrations fall to less than 50% of their initial value in the ﬁrst post-operative year have a low
(<3%) risk of having recurrence detected during the subsequent ﬁve years of follow-up, compared with
those displaying less than a 50% TgAb decline or a TgAb rise during the ﬁrst post-operative year [47].
The favorable prognostic signiﬁcance of a >50% post-operative TgAb decline is seen even though TgAb
becomes undetectable within the ﬁrst post-operative year in only a minority (w30%) of cases [7].
Shown in Fig. 4 is the clinical signiﬁcance of TgAb trends analyzed over the ﬁrst 3–5 post-operative
years as; (a) a falling TgAb trend (to <50% of the initial value); (b) a stable TgAb (less than a 50%
change from initial value); or (c) a rising TgAb trend (a >50% sustained rise at any time).TgAb trends during long-term follow-up monitoring
 Falling TgAb trends: During long-term follow-up, approximately 75% of TgAb-positive patients
display a falling TgAb trend in response to treatment (thyroidectomy  radioiodine) [1,5,7]. Such
patients have a lower risk of recurrent/persistent disease (<3%) and usually have no disease
detected by anatomic imaging, despite only half of such patients achieving a TgAb-negative state
[1,5,6,47,64]. It appears that the presence of Tg-secreting thyroid tissue is necessary to sustain
continued TgAb production [1]. However, when TgAb persists at low levels for long periods of time
it is often difﬁcult to determine if the continued source of Tg antigen is a small amount of normal
remnant tissue or a micro-foci of tumor, because even radioiodine treatment may not completely
Fig. 4. Trends in TgAb concentrations versus the risk of having persistent or recurrent disease detected during follow-up of DTC
patients with detectable TgAb at the time of initial treatment.
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suggest that the likelihood of achieving a TgAb-negative state in response to treatment is inversely
related to the initial TgAb concentration, so that TgAb is less likely to become undetectable in
patients with a high TgAb concentration at the time of initial surgery [7].
 Stable TgAb: In approximately 20% of patients, TgAb declines but only to a minor degree in the year
following thyroidectomy and then plateaus and persists without evidence of disease by anatomic
imaging. The maintenance of TgAb could reﬂect continued Tg antigen secretion by small amounts
of remnant tissue, micro-foci of tumor not detected by anatomic imaging [79], or reﬂect long-lived
antibody-producing plasma cells [80]. Patients with stable but signiﬁcantly elevated TgAb con-
centrations have a higher recurrence risk (w20%) and warrant closer follow-up than patients in
whom TgAb progressively declines over time (years) [2,5,64,79].
 Rising TgAb trends: It is well documented that a rising TgAb trend [5,7,64], or a de novo appear-
ance of TgAb [3,5,65,81], is commonly seen in the ﬁrst few months following radioiodine therapy
or ﬁne-needle aspiration biopsy [82] in response to Tg antigen released by damaged cells. These
responses tend to be transient (1–8 months) and should be distinguished from a sustained, pro-
gressive TgAb rise [4,6,7,9,65], or sustained de novo appearance of TgAb [5,47,81], that may be an
early indicator of recurrence.Practice points
1. For TgAb-positive patients, the TgAb trend is a more reliable tumor marker than Tg IMA.
2. Closer follow-up is warranted when TgAb persists for years without declining.
3. Lymphocytic thyroiditis on the pathology report suggests TgAb maybe occult and cause
falsely low Tg IMA.
4. Ensure laboratories notify physicians before changing Tg or TgAb methods to facilitate re-
baselining.
5. TgAb and Tg method functional sensitivities and between-run precisions should be estab-
lished using human serum pools measured over 6–12months according to current guidelines
[38].
Research agenda
1. Studies of the pathologic signiﬁcance of heterogeneous serum TgAb-Tg speciﬁcity and how
this impacts TgAb and Tg measurements.
2. Long-term prospective studies are needed on whether the association between PTC and
lymphocytic thyroiditis is cause or effect, and relationships between lymphocytic thyroiditis
and outcome.
3. Studies are needed to assess whether the Tg complexed with TgAb has a different metabolic
clearance rate than from free Tg.
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